Abstract
Despite several recent therapeutic advances, multiple myeloma (MM) is still considered an incurable disease. Allogenic transplantation (allo-SCT) is a potential curative treatment for these patients. However, the high morbidity and mortality associated with the procedure makes necessary to identify which are the best candidates and the most adequate timing to perform it. Aim: To analyze the impact of disease characteristics at diagnosis and at the time of allo-SCT in overall survival (OS) and progression-free survival (PFS) in patients with MM treated with proteasome inhibitors (PI) and/or immunomodulatory drugs (IMiDs).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
